本文へ

当サイトでは、利用測定やトラフィック分析を目的として、クッキー(Cookie)を利用しています。
「同意する」ボタンや本サイトをクリックすることで、クッキーの利用に同意いただいたことになります。
詳しくはプライバシーポリシー別ウィンドウで開くをご覧ください。

同意する

ATLAS Asia Clinical Trials Network for Cancers Project
menu
  1. ホーム
  2. 各室員・研究員プロフィール
  3. YONEMORI Kan (米盛 勧)

YONEMORI Kan (米盛 勧) , MD, PhD

職名(所属)
腫瘍内科長、ATLASプロジェクト研究統括、国際開発部門副部門長
施設名

国立がん研究センター 中央病院(日本)

診療科 腫瘍内科
米盛 勧の写真

Dr. 米盛 勧’s Story

2020年から腫瘍内科科長であり、国立がん研究センター中央病院の先端医療科(フェーズIユニット)の共同スタッフ医師です。また私は、医薬品医療機器総合機構で医学評論家の経験があり、米国国立癌研究所と食品医薬品局の客員研究員を経験しました。

乳がん、婦人科がん、胚細胞腫瘍、肉腫、その他の希少がんの専門医の1人です。国立がん研究センター中央病院の主任研究員として、様々ながんの第I相試験から第II/III相試験まで、がん領域の医薬品開発現場をリードしています。

研究対象

腫瘍内科、医薬品開発、規制科学および国際協力。

経歴

2021-現在 国立がん研究センター中央病院 腫瘍内科 科長
2020-2021 国立がん研究センター中央病院 乳腺・腫瘍内科 科長
2015-2020 国立がん研究センター中央病院 乳腺・腫瘍内科 病棟医長
2013-2015 国立がん研究センター中央病院 乳腺・腫瘍内科 医長
2010-2013 国立がん研究センター中央病院 乳腺・腫瘍内科 医員

研究実績

First-in-human study of ONO-4578, an antagonist of prostaglandin E(2) receptor 4, alone and with nivolumab in solid tumors. Cancer Sci, 2022

Iwasa S, Koyama T, Nishino M, Kondo S, Sudo K, Yonemori K, Yoshida T, Tamura K, Shimizu T, Fujiwara Y, Kitano S, Shimomura A, Sato J, Yokoyama F, Iida H, Kondo M, Yamamoto N

  • 論文
Clinical utility of comprehensive genomic profiling tests for advanced or metastatic solid tumor in clinical practice. Cancer Sci 113:4300-4310, 2022

Ida H, Koyama T, Mizuno T, Sunami K, Kubo T, Sudo K, Tao K, Hirata M, Yonemori K, Kato K, Okusaka T, Ohe Y, Matsui Y, Yamazaki N, Ogawa C, Kawai A, Narita Y, Esaki M, Yamamoto N

  • 論文
Practical consideration for successful sequential tumor biopsies in first-in-human trials. Invest New Drugs 40:841-849, 2022

Koyama T, Shimizu T, Sato J, Katsuya Y, Iwasa S, Kondo S, Yoshida T, Sudo K, Nishino M, Takiguchi Y, Yonemori K, Yamamoto N

  • 論文
Dose Escalation Data from the Phase 1 Study of the Liposomal Formulation of Eribulin (E7389-LF) in Japanese Patients with Advanced Solid Tumors. Clin Cancer Res 28:1783-1791, 2022

Sato J, Shimizu T, Koyama T, Iwasa S, Shimomura A, Kondo S, Kitano S, Yonemori K, Fujiwara Y, Tamura K, Suzuki T, Takase T, Nagai R, Yamaguchi K, Semba T, Zhao ZM, Ren M, Yamamoto N

  • 論文
Critical Appraisal of Adjuvant Platinum-Based Chemotherapy for Basal Subtype Triple-Negative Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy.

Shimoi T, Noguchi E, Sudo K, Chua YJ, Yonemori K

  • 論文
Hotspot mutation profiles of AKT1 in Asian women with breast and endometrial cancers.

Shimoi T, Hashimoto J, Sudo K, Shimomura A, Noguchi E, Shimizu C, Yunokawa M, Yonemori K, Yoshida H, Yoshida M, Kato T, Kinoshita T, Fukuda T, Fujiwara Y, Tamura K

  • 論文
Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA). J Clin Oncol. 2021 Sep 2:JCO2100334. doi: 10.1200/JCO.21.00334

Hamanishi J, Takeshima N, Katsumata N, Ushijima K, Kimura T, Takeuchi S, Matsumoto K, Ito K, Mandai M, Nakai H, Sakuragi N, Watari H, Takahashi N, Kato H, Hasegawa K, Yonemori K, Mizuno M, Takehara K, Niikura H, Sawasaki T, et al.

  • 論文
Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study. Lancet Oncol. 2021 Jul;22(7):1034-1046.

Pujade-Lauraine E, Fujiwara K, Ledermann JA, Oza AM, Kristeleit R, Ray-Coquard IL, Richardson GE, Sessa C, Yonemori K, Banerjee S, Leary A, Tinker AV, Jung KH, Madry R, Park SY, Anderson CK, Zohren F, Stewart RA, Wei C, Dychter SS, et al.

  • 論文
First-in-Human Phase 1 Study of MORAb-202, an Antibody-Drug Conjugate Comprising Farletuzumab Linked to Eribulin Mesylate, in Patients with Folate Receptor-α-Positive Advanced Solid Tumors. Clin Cancer Res. 2021 Jul 15;27(14):3905-3915.

Shimizu T, Fujiwara Y, Yonemori K, Koyama T, Sato J, Tamura K, Shimomura A, Ikezawa H, Nomoto M, Furuuchi K, Nakajima R, Miura T, Yamamoto N

  • 論文
Histopathological features of HER2 overexpression in uterine carcinosarcoma: proposal for requirements in HER2 testing for targeted therapy. Virchows Arch. 2021 Jun;478(6):1161-1171.

Yoshida H, Nishikawa T, Matsumoto K, Mori M, Hirashima Y, Takehara K, Ariyoshi K, Hasegawa K, Yonemori K

  • 論文
Regulatory and Operational Challenges in Conducting Asian International Academic Trial for Expanding the Indications of Cancer Drugs. Clin Transl Sci. 2021;14:1015-1025.

Hata T, Nakamura K, Yonemori K, Noguchi E, Watanabe M, Sohn J, Lu YS, Yap YS, Tamura K, Fuiwara Y

  • 論文
First-in-human study of the cancer peptide vaccine TAS0313 in patients with advanced solid tumors. Cancer Sci. 2021 Apr;112(4):1514-1523.

Kondo S, Shimizu T, Koyama T, Sato J, Iwasa S, Yonemori K, Fujiwara Y, Shimomura A, Kitano S, Tamura K, Yamamoto N

  • 論文
The safety, tolerability and pharmacokinetics of niraparib in Japanese patients with solid tumours: results of a phase I dose-escalation study. Jpn J Clin Oncol. 2021 Apr 30;51(5):693-699.

Yonemori K, Shimizu T, Kondo S, Iwasa S, Koyama T, Kitano S, Sato J, Shimomura A, Shibaki R, Suri A, Kase Y, Sumino S, Tamura K, Yamamoto N

  • 論文
Efficacy of second-line treatment and prognostic factors in patients with advanced malignant peritoneal mesothelioma: a retrospective study.

Kitadai R, Shimoi T, Sudo K, Noguchi E, Nagata Y, Sawada R, Takashima A, Boku N, Yonemori K

  • 論文
Impact of ALK Inhibitors in Patients With ALK-Rearranged Nonlung Solid Tumors. JCO Precision Oncology. 2021(5):756-66.

Takeyasu Y, Okuma HS, Kojima Y, Nishikawa T, Tanioka M, Sudo K, Tatsunori Shimoi , Emi Noguchi, Ayumu Arakawa, Taisuke Mori, Kuniko Sunami, Takashi Kubo, Takashi Kohno, Yoshida Akihiko, Noboru Yamamoto, Kan Yonemori, et al.

  • 論文
Safety and Evidence of Off-Label Use of Approved Drugs at the National Cancer Center Hospital in Japan. JCO Oncol Pract. 2021;17(3):e416-e425.

Bun S, Yonemori K, Sunadoi H, Nishigaki R, Noguchi E, Okusaka T, Nishida T, Fujiwara Y

  • 論文
ALK-positive Histiocytosis of the Breast: A Clinicopathologic Study Highlighting Spindle Cell Histology. Am J Surg Pathol. 2021 Mar 1;45(3):347-355.

Kashima J, Yoshida M, Jimbo K, Izutsu K, Ushiku T, Yonemori K, Yoshida A

  • 論文
Safety and Evidence of Off-Label Use of Approved Drugs at the National Cancer Center Hospital in Japan. JCO Oncol Pract. 2021 Mar;17(3):e416-e425

Bun S, Yonemori K, Sunadoi H, Nishigaki R, Noguchi E, Okusaka T, Nishida T, Fujiwara Y

  • 論文
Breast Cancer Brain Metastasis-Overview of Disease State, Treatment Options and Future Perspectives

Chikashi Watase, Sho Shiino, Tatsunori Shimoi, Emi Noguchi, Tomoya Kaneda, Yusuke Yamamoto, Kan Yonemori, Shin Takayama, Akihiko Suto

  • 論文
Vaginal Transmission of Cancer from Mothers with Cervical Cancer to Infants. N Engl J Med. 2021;384(1):42-50.

Arakawa A, Ichikawa H, Kubo T, Motoi N, Kumamoto T, Nakajima M, Yonemori K, Noguchi E, Sunami K, Shiraishi K, Kakishima H, Yoshida H, Hishiki T, Kawakubo N, Kuroda T, Kiyokawa T, Yamada K, Yanaihara N, Takahashi K, Okamoto A, et al.

  • 論文
Neoadjuvant chemotherapy promotes the expression of HER3 in patients with ovarian cancer. Oncol Lett. 2020 Dec;20(6):336.

Mizuno T, Kojima Y, Yonemori K, Yoshida H, Sugiura Y, Ohtake Y, Okuma HS, Nishikawa T, Tanioka M, Sudo K, Shimomura A, Noguchi E, Kato T, Shimoi T, Uno M, Ishikawa M, Fujiwara Y, Ohe Y, Tamura K

  • 論文
MASTER KEY Project: Powering Clinical Development for Rare Cancers Through a Platform Trial. Clin Pharmacol Ther. 2020 Sep;108(3):596-605.

Okuma HS, Yonemori K, Narita SN, Sukigara T, Hirakawa A, Shimizu T, Shibata T, Kawai A, Yamamoto N, Nakamura K, Nishida T, Fujiwara Y

Visualization of the distribution of nanoparticle-formulated AZD2811 in mouse tumor model using matrix-assisted laser desorption ionization mass spectrometry imaging. Sci Rep. 2020 Sep 23;10(1):15535.

Ryu S, Ohuchi M, Yagishita S, Shimoi T, Yonemori K, Tamura K, Fujiwara Y, Hamada A

  • 論文
Response to Dabrafenib and Trametinib of a Patient with Metaplastic Breast Carcinoma Harboring a BRAF V600E Mutation. Case Rep Oncol Med. 2020;2020:2518383

Seo T, Noguchi E, Yoshida M, Mori T, Tanioka M, Sudo K, Shimomura A, Yonemori K, Fujiwara Y, Tamura K

  • 論文
First-in-human phase I study of E7090, a novel selective fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors. Cancer Sci 111:571-579, 2020

Koyama T, Shimizu T, Iwasa S, Fujiwara Y, Kondo S, Kitano S, Yonemori K, Shimomura A, Iizumi S, Sasaki T, Furuse J, Yamamoto N

  • 論文
Treatment Outcome of Second-Line Chemotherapy for Gynecologic Carcinosarcoma. Oncology. 2020;98(10):699-705.

Ebata T, Yonemori K, Nishikawa T, Sudo K, Shimomura A, Noguchi E, et al.

  • 論文
Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network. Cancer. 2020;126(1):98-104.

Frezza AM, Assi T, Lo Vullo S, Ben-Ami E, Dufresne A, Yonemori K, Noguchi E, Siontis B, Ferraro R, Teterycz P, Duffaud F, Ravi V, Vincenzi B, Gelderblom H, Pantaleo MA, Baldi GG, Desar I, Fedenko A, Maki RG, Jones RL, et al.

  • 論文
A Comparative Study of Longitudinal Toxicities of Cytotoxic Drugs, Molecularly Targeted Agents, Immunomodulatory Drugs, and Cancer Vaccines. Clin Pharmacol Ther. 2019 Oct;106(4):803-809.

Hirakawa A, Sudo K, Yonemori K, Sadachi R, Kinoshita F, Kobayashi Y, Okuma HS, Kawachi A, Tamura K, Fujiwara Y, Rubinstein L, Takebe N

  • 論文
Bone marrow examination in patients with Ewing sarcoma/peripheral primitive neuroectodermal tumor without metastasis based on 18F-fluorodeoxyglucose positron emission tomography/computed tomography.

Inagaki C, Shimoi T, Sumiyoshi Okuma H, Kawachi A, Sudo K, Shimomura A, Noguchi E, Kodaira M, Yunokawa M, Yonemori K, Shimizu C, Arakawa A, Ogawa C, Yoshida A, Fujiwara Y, Tamura K

  • 論文
The Incidence of Nonmalignant Diseases among Patients with Suspected Carcinoma of Unknown Primary Site.

Sato J, Shimoi T, Shimomura A, Noguchi E, Kodaira M, Yunokawa M, Yonemori K, Shimizu C, Fujiwara Y, Yoshida M, Tamura K

  • 論文
A Comparative Study of Longitudinal Toxicities of Cytotoxic Drugs, Molecularly Targeted Agents, Immunomodulatory Drugs, and Cancer Vaccines. Clinical Pharmacology & Therapeutics. 2019;106 (4), 803-809.

A Hirakawa, K Sudo, K Yonemori, R Sadachi, F Kinoshita, Y Kobayashi, HS Okuma, A Kawachi, K Tamura, Y Fujiwara, L Rubinstein, N Takebe

  • 論文
Feasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting: A hospital-based study. Cancer science 110(4): 1480-1490 (2019)

Sunami Kuniko, Ichikawa Hitoshi, Kubo Takashi, Kato Mamoru, Fujiwara Yutaka, Shimomura Akihiko, Koyama Takafumi, Kakishima Hiroki, Kitami Mayuko, Matsushita Hiromichi, Furukawa Eisaku, Narushima Daichi, Nagai Momoko, Taniguchi Hirokazu, Motoi Noriko, Sekine Shigeki, Yonemori Kan , Tanabe Noriko , Yamamoto Noboru, Kohno Takashi, et al.

  • 論文
Utility of Bayesian Single-Arm Design in New Drug Application for Rare Cancers in Japan: A Case Study of Phase 2 Trial for Sarcoma. Ther Innov Regul Sci. 2018;52(3):334-8.

Hirakawa A, Nishikawa T, Yonemori K, Shibata T, Nakamura K, Ando M, et al.

  • 論文
Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study. Lancet Oncol. 2017 Nov;18(11):1512-1522.

Doi T, Shitara K, Naito Y, Shimomura A, Fujiwara Y, Yonemori K, Shimizu C, Shimoi T, Kuboki Y, Matsubara N, Kitano A, Jikoh T, Lee C, Fujisaki Y, Ogitani Y, Yver A, Tamura K

  • 論文
Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study.

Doi T, Shitara K, Naito Y, Shimomura A, Fujiwara Y, Yonemori K, Shimizu C, Shimoi T, Kuboki Y, Matsubara N, Kitano A, Jikoh T, Lee C, Fujisaki Y, Ogitani Y, Yver A, Tamura K

  • 論文
BRCA Gene Mutations and Poly(ADP-Ribose) Polymerase Inhibitors in Triple-Negative Breast Cancer. Adv Exp Med Biol. 2017;1026:271-286.

Okuma HS, Yonemori K

  • 論文
Comparison of dose intensity of vincristine, d-actinomycin, and cyclophosphamide chemotherapy for child and adult rhabdomyosarcoma: a retrospective analysis. Cancer Chemother Pharmacol. 2012 9 70:391-397

Kojima Y, Hashimoto K, Ando M, Yonemori K, Yamamoto H, Kodaira M, Yunokawa M, Shimizu C, Tamura K, Hosono A, Makimoto A, Fujiwara Y

  • 論文
PAGE TOP